Clinical trials: Nutritional Evaluation
Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
- Trial name
- NCT07465224
- Testing
- ALN-4324
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Alnylam Pharmaceuticals
Fabry Disease
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
Primary Objective: To assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and exploratory efficacy of GZ/SAR402671 in enzyme replacement therapy treatment-naïve adult male participants diagnosed with Fabry disease.
- Trial name
- NCT02228460
- Testing
- GZ/SAR402671
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Genzyme, a Sanofi Company
Hyperlipidemia
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin.
- Trial name
- NCT07216482
- Testing
- Enlicitide, Rosuvastatin
- Where
- 87 sites in United States, Argentina and 9 more
- Volunteers
- 996 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus, Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"
The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-1" and "BR1019-2" in healthy volunteers
- Trial name
- NCT06226727
- Testing
- BR1019, BR1019-1, BR1019-2
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Dyslipidemias
To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults
This study is designated to evaluate the pharmacokinetic interactions of valsartan, amlodipine besylate, rosuvastatin, and ezetimibe in healthy male volunteers.
- Trial name
- NCT04185090
- Testing
- ID1803, ID1801, ID1803+ID1801
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
Osteoporosis
Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-101 in healthy volunteers
- Trial name
- NCT03764462
- Testing
- AD-101 45mg, Raloxifene 60mg
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Gout, Gouty Arthritis
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase).
- Conditions
- Gout, Gouty Arthritis, Hyperuricemia, Gout Chronic
- Trial name
- NCT07116746
- Testing
- AR882 75 mg, XOI Low Dose, XOI High Dose
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Arthrosi Therapeutics
PreDiabetes, Aging
Safety and Efficacy of KH-1 for Stimulating Autophagy in Non-diabetic Adults With Elevated Blood Glucose Concentration
Aging significantly impacts overall health and is a risk factor for developing diabetes. An estimated 50% of U.S. adults aged ≥65 years were reported to have prediabetes (defined as having a fasting glucose concentration of…
- Trial name
- NCT06445569
- Testing
- KH-1
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Kalin Health, LLC
Dyslipidemias
Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506
To evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant administration of YYC506-T and YYC506-A
- Trial name
- NCT04874129
- Testing
- YYC506-T and YYC506-A (phase 1), YYC506 (phase 1), YYC506-T and YYC506-A (phase 2)
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Diabetes Mellitus
Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease
The use of acarbose in impaired glucose tolerance (IGT) and type 2 diabetic subjects has been associated with a significant reduction of cardiovascular events.
- Trial name
- ABDOMEN (NCT01167231)
- Testing
- Acarbose (Glucobay, BAYG5421)
- Where
- Poland
- Volunteers
- 3,310 people
- Sponsor
- Bayer
Healthy Volunteers
A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants
The purpose of this study is to evaluate the relative bioavailability of fedratinib in healthy adult participants.
- Trial name
- NCT05051553
- Testing
- Fedratinib
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type 2
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
- Trial name
- THEMIS (NCT01991795)
- Testing
- Ticagrelor 60 mg
- Where
- 1,237 sites in United States, Argentina and 41 more
- Volunteers
- 19,271 people
- Sponsor
- AstraZeneca
Niemann-Pick Type C Disease
Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System
This study was amended from expanded access to a clinical trial. Information will be collected about long-term safety and effectiveness of adrabetadex shots in the spine every 2 weeks.
- Trial name
- NCT03643562
- Testing
- Adrabetadex
- Where
- 17 sites in United States
- Volunteers
- 27 people
- Sponsor
- Mandos LLC
Dyslipidemia, Coronary Heart Disease
Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + simvastatin combination therapy with ABT-335 and simvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood.
- Conditions
- Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
- Trial name
- NCT00300456
- Testing
- ABT-335, Simvastatin
- Where
- United States
- Volunteers
- 657 people
- Sponsor
- Abbott
Obesity
A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity
The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: how the study medicine, danuglipron, is taken up into the…
- Trial name
- NCT06568731
- Testing
- Danuglipron
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Study of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss
The aim of the study was to compare 5 methods of delivering a weight loss lifestyle modification program to obese patients on a background of sibutramine.
- Trial name
- NCT00471172
- Testing
- Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week), Face-to-face counseling by a dietitian (monthly), Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)
- Where
- 12 sites in United States
- Volunteers
- 350 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus, Obesity
To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants
XW003 is an acylated human GLP-1 analogue and is being development for diabetes mellitus, obesity and nonalcoholic steatohepatitis (NASH) management.
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Nonalcoholic Steatohepatitis
- Trial name
- XW003 (NCT04389775)
- Testing
- Cohort A, Cohort B
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Congenital Adrenal Hyperplasia, 21-OHD
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH
An investigation of the safety and efficacy of tildacerfont in participants with CAH.
- Trial name
- NCT05128942
- Testing
- Tildacerfont
- Where
- 13 sites in United States
- Volunteers
- 67 people
- Sponsor
- Spruce Biosciences
Overweight, Obesity
A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity
The study is testing the new medicine NNC0662-0419 in people living with overweight or obesity. The purpose of the study is to look into the amount of the new medicine NNC0662-0419 in participants blood after one dose.
- Trial name
- NCT07101783
- Testing
- NNC0662-0419
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Novo Nordisk A/S
Obesity, Nutritional and Metabolic Diseases
A Study of the Safety of R256918 in Obese Patients
This study investigates the safety of 12 weeks of treatment with R256918, in obese patients (JNJ-16269110 and R256918 are different names for the same molecule).
- Conditions
- Obesity, Nutritional and Metabolic Diseases, Metabolic Diseases, Nutrition Disorders
- Trial name
- NCT01041677
- Testing
- R256918
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 71 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.